Xeris Biopharma Holdings, Inc. — Form 8-K Summary
Business context and reporting period
Filed March 6, 2024, regarding events occurring March 5–6, 2024. Xeris Biopharma Holdings, Inc. and subsidiaries reported a refinancing transaction and furnished a press release regarding fourth-quarter and full-year 2023 results. The filing does not include the financial results press release text.
Material financing and financial metrics
- Refinancing: The company entered into an amended and restated credit agreement with Hayfin Services LLP and new lenders.
- Term loans: The facility provides $200.0 million of Tranche 1 Loans at closing and up to $15.2 million of additional Tranche 2 Loans through July 15, 2025.
- Existing debt: $150.0 million of principal, plus accrued and unpaid interest, under the prior credit agreement was continued under the new agreement. The prior agreement was otherwise repaid in full.
- Use of proceeds: Tranche 1 proceeds may be used for general corporate purposes. Tranche 2 proceeds may only be used to redeem the 5.00% Convertible Senior Notes due 2025.
- Maturity: The loans mature March 5, 2029, subject to earlier maturity provisions tied to the company’s 2025 and 2028 convertible notes.
- Interest rate: A floating rate equal to 6.95% plus the greater of three-month term SOFR or 2.00%; the spread is 5.95% if a replacement rate applies.
- Collateral: The company and subsidiary guarantors granted a first-priority security interest in substantially all assets, including intellectual property, subject to exceptions.
- Other metrics: Revenue, profit, cash flow, margins, cash balance, liquidity, and operating results for 2023 are not provided in the filing text. The filing refers investors to Exhibit 99.1, which is not included in the supplied content.
Material changes versus the prior comparable period
- The filing documents a substantial refinancing of the existing credit facility and continuation of $150.0 million of existing principal under new 2029 Loans.
- The company obtained additional borrowing capacity of up to $15.2 million, restricted to redeeming the 2025 Convertible Notes.
- The new facility introduces a five-year stated maturity, floating-rate debt, collateral requirements, prepayment premiums, and expanded financial and operational restrictions.
- The filing references fourth-quarter and full-year 2023 results, but does not provide comparable-period financial data or quantified changes.
Guidance, outlook, risks, contingencies, and unusual items
- The loans cannot be re-borrowed after repayment and are subject to early prepayment fees, including a make-whole amount during the first two years and premiums of 5% or 3% during portions of years three and four.
- The loans may mature as early as January 15, 2025 if the 2025 Convertible Notes remain outstanding and specified refinancing, repayment, or equity-raising conditions are not satisfied.
- The loans may mature as early as January 15, 2028 if the 2028 Convertible Notes remain outstanding and similar conditions are not satisfied.
- The company is subject to customary covenants restricting additional debt, liens, acquisitions, investments, dividends, equity repurchases, asset dispositions, mergers, and certain affiliate transactions, subject to exceptions.
- The filing provides no quantified operating guidance or outlook. Management commentary and business highlights are contained in referenced press releases that were not supplied.
Key facts for investor verification
- Verify the complete terms, definitions, covenants, events of default, and collateral provisions in the credit agreement when filed with the company’s Form 10-Q for the quarter ended March 31, 2024.
- Confirm the company’s 2023 revenue, profitability, cash flow, cash balance, liquidity, and year-over-year trends using Exhibit 99.1 or the related earnings materials.
- Assess the refinancing’s effect on near-term liquidity, interest expense, and maturity risk for the 2025 and 2028 convertible notes.
- Review the company’s ability to satisfy the early-maturity conditions, including permitted equity or convertible-debt raises and the stated use of no more than $15.6 million of cash on hand.
- Evaluate exposure to floating interest rates, prepayment premiums, pledged intellectual property, and restrictive debt covenants.